/
Nephrology
Nephropathy
94
Pipeline Programs↗
135
Active Trials↗
82
Companies Involved↗
Nephropathy is a moderately active landscape with 94 programs across 82 companies. The most active players are Otsuka, Keymed Biosciences Co.Ltd, NovelMed Therapeutics. 25 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical43
Phase 14
Phase 222
Phase 325
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
79 of 88 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 88 classified programs, each share of the total. Modality classified for 97% of 94 pipeline programs.
Analysis
Trial Status
492
clinical trials
Completed223 · 45%
Unknown status83 · 17%
Recruiting61 · 12%
Not yet recruiting47 · 10%
Terminated35 · 7%
Active, not recruiting21 · 4%
Other22 · 4%
Clinical Trials
Trial Activity
492 trials
Page 1 of 33
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)